[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2438238A1 - Composition et procede de traitement de troubles inflammatoires - Google Patents

Composition et procede de traitement de troubles inflammatoires Download PDF

Info

Publication number
CA2438238A1
CA2438238A1 CA002438238A CA2438238A CA2438238A1 CA 2438238 A1 CA2438238 A1 CA 2438238A1 CA 002438238 A CA002438238 A CA 002438238A CA 2438238 A CA2438238 A CA 2438238A CA 2438238 A1 CA2438238 A1 CA 2438238A1
Authority
CA
Canada
Prior art keywords
protein
antibody
cells
subject
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438238A
Other languages
English (en)
Inventor
Kenneth Jacobs
Debra D. Pittman
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438238A1 publication Critical patent/CA2438238A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)

Abstract

La présente invention concerne des inhibiteurs de IL-22 ainsi que des compositions pharmaceutiques et de procédés mettant en oeuvre lesdits inhibiteurs. Les inhibiteurs comprennent des anticorps de IL-22 et sont utiles pour le traitement des troubles inflammatoires. FIG. 1 : A PROTOCOLE CIA DANS DES SOURIS DBA. MODELE DE SOURIS POUR LE POLYARTHRITE RHUMATOIDE B REGIME PROPHYLACTIQUE F JOUR 0 IMMUNISATION AVEC DU COLLAGENE BOVIN ET L'ADJUVANT DE FREUND INCOMPLETE 21?e¿ JOUR IMMUNISATION AVEC DU COLLAGENE BOVIN ET L'ADJUVANT COMPLET DE FREUND C REACTIF DE TEST : DEBUT 21?e¿ JOUR, 200 µg/SOURIS, 2 FOIS PAR SEMAINE D PREMIERES INDICATIONS DE MALADIE ENVIRON AU 23?e¿ JOUR G REACTIF DE TEST H REGIME THERAPEUTIQUE I ENVIRON AU 40?e¿ JOUR OU APRES
CA002438238A 2001-02-23 2002-02-25 Composition et procede de traitement de troubles inflammatoires Abandoned CA2438238A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27082301P 2001-02-23 2001-02-23
US60/270,823 2001-02-23
US28135301P 2001-04-03 2001-04-03
US60/281,353 2001-04-03
PCT/US2002/005684 WO2002068476A2 (fr) 2001-02-23 2002-02-25 Composition et procede de traitement de troubles inflammatoires

Publications (1)

Publication Number Publication Date
CA2438238A1 true CA2438238A1 (fr) 2002-09-06

Family

ID=26954516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438238A Abandoned CA2438238A1 (fr) 2001-02-23 2002-02-25 Composition et procede de traitement de troubles inflammatoires

Country Status (9)

Country Link
EP (1) EP1373319A2 (fr)
JP (2) JP2005510451A (fr)
AU (2) AU2002252097A2 (fr)
BR (1) BR0207528A (fr)
CA (1) CA2438238A1 (fr)
MX (1) MXPA03007413A (fr)
NZ (1) NZ527396A (fr)
WO (1) WO2002068476A2 (fr)
ZA (1) ZA200306071B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
CA2438238A1 (fr) * 2001-02-23 2002-09-06 Genetics Institute, Llc. Composition et procede de traitement de troubles inflammatoires
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2003083062A2 (fr) * 2002-03-22 2003-10-09 Zymogenetics, Inc. Anticorps anti-il-tif et leurs methodes d'utilisation dans une inflammation
CN103864934A (zh) 2003-03-24 2014-06-18 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣以及在炎症中的使用方法
KR20060022289A (ko) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
MX2007004770A (es) 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
EP2192132A3 (fr) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anticorps et partenaires de liaison anti-il-20, anti-il-22 et anti-il-22ra, et methodes d'utilisation de ces anticorps et partenaires de liaison dans des processus inflammatoires
RU2426742C2 (ru) * 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP3385277A1 (fr) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Polypeptides il-22 et protéines de fusion fc il-22 et leurs procédés d'utilisation
SG11202012014UA (en) 2018-06-05 2021-01-28 Bioatla Inc Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2023110942A1 (fr) * 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prévention de guérison d'une fracture altérée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
WO2000024758A1 (fr) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Molecules d'acide nucleique isolees codant pour des facteurs inductibles derives de lymphocytes t (tif), proteines codees et leur utilisation
ES2530857T3 (es) * 1999-04-28 2015-03-06 Genetics Inst Llc Proteínas GIL-19/AE289 humanas y polinucleótidos que codifican las mismas
ATE459716T1 (de) * 1999-12-23 2010-03-15 Zymogenetics Inc Zytokin zcyt018
CA2438238A1 (fr) * 2001-02-23 2002-09-06 Genetics Institute, Llc. Composition et procede de traitement de troubles inflammatoires

Also Published As

Publication number Publication date
EP1373319A2 (fr) 2004-01-02
WO2002068476A2 (fr) 2002-09-06
AU2008203342B2 (en) 2011-02-17
ZA200306071B (en) 2005-11-30
MXPA03007413A (es) 2003-11-18
AU2008203342A1 (en) 2008-08-14
NZ527396A (en) 2007-12-21
AU2008203342B8 (en) 2011-03-17
JP2005510451A (ja) 2005-04-21
JP2009137986A (ja) 2009-06-25
BR0207528A (pt) 2006-01-17
WO2002068476A3 (fr) 2003-08-07
AU2002252097A2 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US7279559B2 (en) Antibodies that bind to interleukin-22
AU2008203342B8 (en) Composition and method for treating inflammatory disorders
US8048984B2 (en) Human GIL-19/AE289 proteins
EP2357193B1 (fr) Protéines GIL-19/AE289 humaines et polynucléotides les codant
US20020142952A1 (en) Polynucleotides encoding novel secreted proteins
US20030027139A1 (en) Polynucleotides encoding novel secreted proteins
US20020045170A1 (en) Polynucleotides encoding novel secreted proteins
US20020039760A1 (en) Polynucleotides encoding novel secreted proteins
AU764191B2 (en) Human GIL-19/AE289 proteins and polynucleotides encoding same
EP1897950B1 (fr) Protéines GIL-19/AE289 humaines et polynucléotides les codant
AU2003262307B2 (en) Human GIL-19/AE289 proteins and polynucleotides encoding same
TWI332008B (en) Human il-22/gil-19/ae289 proteins and polynucleotides encoding same
WO1999050435A1 (fr) Gpi-122, nouvelle proteine ancree au glycophosphatidylinotisol
US20020150563A1 (en) GPI-122, a novel glycophosphatidylinositol-anchored protein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20131204